Abstract
Abstract 13294: Effect of Alirocumab on Estimated Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein (a) Cholesterol: Pooled Analysis From 5 ODYSSEY Phase 3 Studies
Circulation (New York, N.Y.), Vol.140(Suppl_1 Suppl 1), pp.A13294-A13294
11/19/2019
DOI: 10.1161/circ.140.suppl_1.13294
Abstract
BackgroundCurrent clinical methods for estimation or direct measurement of low-density lipoprotein cholesterol (LDL-C) include the content of cholesterol on lipoprotein (a) (Lp(a)-C), which may mask changes in true LDL (LDL-Ccorr) in therapeutic interventions.MethodsThe effect of alirocumab (75-150 mg every 2 weeks) or placebo in patients (alirocumab, n=1983; placebo, n=1011) on laboratory measured “LDL-C” and estimated LDL-Ccorr was analyzed in 5 ODYSSEY phase 3 studies using paired LDL-C and Lp(a) mass levels at baseline and at 24 weeks. LDL-C was estimated by the Friedewald formula or measured directly by beta-quantitation if triglycerides >400 mg/dL. Lp(a)-C was estimated as Lp(a) mass in mg/dL times 0.30. LDL-Ccorr was calculated as LDL-C minus Lp(a)-C. Additional analyses were carried out by categories of increasing Lp(a) levels (0-30, 30-50, 50-100, and >100 mg/dL).ResultsAt baseline, mean (SD) LDL-Ccorr levels were lower than LDL-C in both alirocumab and placebo groups and LDL-Ccorr declined progressively with higher Lp(a) levels (Table). In the entire group, alirocumab resulted in a greater reduction in LDL-Ccorr versus LDL-C (63.3% vs 58.8%, p<0.001). This was more evident as Lp(a) levels increasedLp(a)0-30 mg/dL (60.2% vs 59.5%, p<0.001), 30-50 mg/dL (63.1% vs 59.3%, p<0.001), 50-100 mg/dL (66.5% vs 58.4%, p<0.001), and >100 mg/dL (70.7% vs 55.7%, p<0.001).ConclusionAlirocumab results in a progressively greater reduction in estimated LDL-Ccorr versus LDL-C as Lp(a) increases. The true effect of alirocumab on LDL-Ccorr may be masked by methodological limitations in accurately measuring LDL-C versus Lp(a)-C.
Details
- Title: Subtitle
- Abstract 13294: Effect of Alirocumab on Estimated Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein (a) Cholesterol: Pooled Analysis From 5 ODYSSEY Phase 3 Studies
- Creators
- Sotirios Tsimikas - University of California, San DiegoJennifer Robinson - University of IowaHelen Li - RegeneronMarc Israel - RegeneronCatherine Domenger - Sanofi Val De Bievre, Gentilly, FranceDaniel Gaudet - Université de Montréal
- Resource Type
- Abstract
- Publication Details
- Circulation (New York, N.Y.), Vol.140(Suppl_1 Suppl 1), pp.A13294-A13294
- Publisher
- by the American College of Cardiology Foundation and the American Heart Association, Inc
- DOI
- 10.1161/circ.140.suppl_1.13294
- ISSN
- 0009-7322
- eISSN
- 1524-4539
- Language
- English
- Date published
- 11/19/2019
- Academic Unit
- Fraternal Order of Eagles Diabetes Research Center; Epidemiology
- Record Identifier
- 9984364394502771
Metrics
11 Record Views